UA106979U - Способ коррекции эндотелиальной дисфункции, ассоциированной с беременностью у женщин с сердечно-сосудистой патологией - Google Patents
Способ коррекции эндотелиальной дисфункции, ассоциированной с беременностью у женщин с сердечно-сосудистой патологией Download PDFInfo
- Publication number
- UA106979U UA106979U UAU201512383U UAU201512383U UA106979U UA 106979 U UA106979 U UA 106979U UA U201512383 U UAU201512383 U UA U201512383U UA U201512383 U UAU201512383 U UA U201512383U UA 106979 U UA106979 U UA 106979U
- Authority
- UA
- Ukraine
- Prior art keywords
- women
- endothelial dysfunction
- arginine
- pregnancy
- dysfunction associated
- Prior art date
Links
- 206010048554 Endothelial dysfunction Diseases 0.000 title claims abstract description 17
- 230000008694 endothelial dysfunction Effects 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 14
- 230000007170 pathology Effects 0.000 title claims abstract description 8
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 7
- 230000035935 pregnancy Effects 0.000 title claims abstract description 6
- 230000000694 effects Effects 0.000 claims abstract description 11
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 claims abstract description 5
- 210000000130 stem cell Anatomy 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 4
- 239000004475 Arginine Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 2
- 229930064664 L-arginine Natural products 0.000 abstract 2
- 235000014852 L-arginine Nutrition 0.000 abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 201000011461 pre-eclampsia Diseases 0.000 description 6
- 208000037849 arterial hypertension Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960000619 nebivolol Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- MSYQJZMDTZWNQZ-UHFFFAOYSA-N 2-[(5-methyl-1h-1,2,4-triazol-3-yl)sulfanyl]acetic acid;morpholine Chemical compound C1COCC[NH2+]1.CC1=NC(SCC([O-])=O)=NN1 MSYQJZMDTZWNQZ-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000141 anti-hypoxic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000002666 vasoprotective effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Способ коррекции эндотелиальной дисфункции, ассоциированной с беременностью у женщин с сердечно-сосудистой патологией, включает базовую терапию. Дополнительно определяется влияние экзогенного L-аргинина на уровень циркулирующих прогениторных клеток и применяется в терапии беременных препарат L-аргинин (Тивортин), который назначается по 100 мл один раз в сутки внутривенно капельно в течение 7 дней, далее по 5 мл перорально в сутки, в течение 14 дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201512383U UA106979U (ru) | 2015-12-15 | 2015-12-15 | Способ коррекции эндотелиальной дисфункции, ассоциированной с беременностью у женщин с сердечно-сосудистой патологией |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201512383U UA106979U (ru) | 2015-12-15 | 2015-12-15 | Способ коррекции эндотелиальной дисфункции, ассоциированной с беременностью у женщин с сердечно-сосудистой патологией |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA106979U true UA106979U (ru) | 2016-05-10 |
Family
ID=57142689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201512383U UA106979U (ru) | 2015-12-15 | 2015-12-15 | Способ коррекции эндотелиальной дисфункции, ассоциированной с беременностью у женщин с сердечно-сосудистой патологией |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA106979U (ru) |
-
2015
- 2015-12-15 UA UAU201512383U patent/UA106979U/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Blood-brain barrier dysfunction mediated by the EZH2-Claudin-5 axis drives stress-induced TNF-α infiltration and depression-like behaviors | |
| Zou et al. | Bone marrow mesenchymal stem cell‑derived exosomes protect against myocardial infarction by promoting autophagy | |
| Zhu et al. | αKlotho protein has therapeutic activity in contrast-induced acute kidney injury by limiting NLRP3 inflammasome-mediated pyroptosis and promoting autophagy | |
| Dong et al. | Lung endothelial barrier protection by resveratrol involves inhibition of HMGB1 release and HMGB1-induced mitochondrial oxidative damage via an Nrf2-dependent mechanism | |
| Qiu et al. | Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica | |
| Tang et al. | Targeting of microRNA-21-5p protects against seizure damage in a kainic acid-induced status epilepticus model via PTEN-mTOR | |
| Peng et al. | Alcohol-induced histone H3K9 hyperacetylation and cardiac hypertrophy are reversed by a histone acetylases inhibitor anacardic acid in developing murine hearts | |
| Xie et al. | 5-aza-2′-deoxycytidine in the regulation of antioxidant enzymes in retinal endothelial cells and rat diabetic retina | |
| Liu et al. | Expression of microRNAs in the plasma of patients with acute gouty arthritis and the effects of colchicine and etoricoxib on the differential expression of microRNAs | |
| WO2017029556A1 (en) | Methods and compositions to treat liver diseases and conditions | |
| Zhu et al. | Long noncoding Mirt2 reduces apoptosis to alleviate myocardial infarction through regulation of the miR-764/PDK1 axis | |
| Zeng et al. | Zafirlukast protects blood-brain barrier integrity from ischemic brain injury | |
| KR20130069633A (ko) | 심혈관 질환의 위험도를 측정하기 위한 수단 및 방법 | |
| Xue et al. | NQO1 mediates lenvatinib resistance by regulating ROS-induced apoptosis in hepatocellular carcinoma | |
| Liu et al. | Intracellular Zn2+ promotes extracellular matrix remodeling in dexamethasone-treated trabecular meshwork | |
| US10874749B2 (en) | Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways | |
| Song et al. | Analysis of differentially expressed genes in placental tissues of preeclampsia patients using microarray combined with the Connectivity Map database | |
| Jin et al. | Elevated mir-145-5p is associated with skeletal muscle dysfunction and triggers apoptotic cell death in C2C12 myotubes | |
| UA106979U (ru) | Способ коррекции эндотелиальной дисфункции, ассоциированной с беременностью у женщин с сердечно-сосудистой патологией | |
| Katerini et al. | Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery | |
| CN107447019A (zh) | piRNA‑12和piRNA‑12抑制剂的应用及应用其的产品 | |
| Yang et al. | Synergetic protective effect of remote ischemic preconditioning and prolyl 4-hydroxylase inhibition in ischemic cardiac injury | |
| Zhang et al. | M2 macrophage derived exosomal miR-20a-5p ameliorates trophoblast pyroptosis and placental injuries in obstetric antiphospholipid syndrome via the TXNIP/NLRP3 axis | |
| TW202120069A (zh) | 植物萃取物用於提升ＣＣＴ基因、Ａｔｇ基因、ＮＡＤＳＹＮ基因、ＭＲＰＳ５基因、ＳＯＤ３基因、及ＴＥＲＴ基因表現量及／或提升ＧＳＨ含量的用途 | |
| RU2079139C1 (ru) | Способ раннего прогнозирования тяжести течения дифтерии у взрослых |